Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
|
|
|
- Clifton Little
- 5 years ago
- Views:
Transcription
1 Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276 Adepto Medical 277 Advanced Care Scripts 174 AMAG Pharmaceuticals 950 Amber Pharmacy 353 American AACR 112 American Cannabis Nurses Association 210 Amgen Inc 1139 Amgen Inc 244 Amgen Inc 617 Aplastic Anemia & MDS International Foundation 131 ApoBiologix 855 Aqua Guard 554 Aquabiliti 241 ASCO 125 ASCO/Cancer.Net 110 ASCO/Cancer.Net 123 Association of Community Cancer Centers 111 Astellas Pharma 901 AstraZeneca 135 AstraZeneca 314 AstraZeneca 406 Avella Specialty Pharmacy 1037 B. Braun Medical 925 Bard 201 Bayer Healthcare 410 Baylor Scott and White Health 877 BD (Becton Dickinson) 753 Billings Clinic 569 Biologics, Inc. 242 BioPlus Specialty Pharmacy 161 BJC HealthCare 775 Boehringer Ingelheim Pharmaceuticals, Inc Boiron 344 BriovaRx 552 Bristol-Myers Squibb 1135 Bristol-Myers Squibb 825 BTG International, Inc. 225 Cancer and Careers 117
2 Care+Wear 175 Case Western Reserve University 966 Celgene Corporation 801 Celgene Corporation 859 Champion Manufacturing, Inc. 558 Chatham University 864 ChemoGLO LLC 1136 Children's Treehouse Foundation, The 127 Christie Medical Holdings 979 City of Hope 122 City of Hope Talent Acquisition 466 Clinical Care Options/InPractice 1075 CLL Society 130 Clovis Oncology 958 Coherus Biosciences 1118 Commcare Pharmacy 461 Corvida Medical 268 Covalon Technologies Ltd CoverMyMeds 247 Cumberland Pharmaceuticals 837 Cure Forward 141 CVS Specialty 168 Daiichi Sankyo, Inc. 348 Dale Medical Products 553 Depomed 1128 Derma Sciences, Inc. 964 Dignitana, Inc. 143 Diplomat Specialty Pharmacy 346 Duke Health 474 Eisai Inc. 611 Eisai Inc. 971 enterade 169 Equashield, LLC 659 Ethicon Biopatch 1134 Exelixis 1058 Exelixis 965 First Descents 124 Flatiron Health 564 Florida Cancer Specialists 765 Florida Hospital 872 Free to Breathe 216 Genentech USA, Inc. 625 Genome Magazine 140 Gilead Sciences, Inc. 860 Goldfarb School of Nursing 766 Grand Canyon University 764 Halyard 279
3 Harborside Press 943 Hawaiian Moon 355 Haymarket Oncology 1027 Health Care Logistics 1119 Helsinn Integrative Care 234 Helsinn Therapeutics (U.S.), Inc 1077 Heron Therapeutics, Inc. 953 Hospital Corporation of America 767 HRA Healthcare Research & Analytics 139 ICU Medical, Inc. 452 ImpediMed 455 Incyte Corporation 335 InfuSystem, Inc. 236 INSYS Therapeutics, Inc. 347 Intellisphere, LLC 559 International Myeloma Foundation 1019 Ipsen Pharmaceuticals 1013 ivwatch, LLC 851 Iwata Label Co., Ltd. 272 Janssen Biotech, Inc 913 Jazz Pharmaceuticals, Inc. 148 Johns Hopkins Health System 570 Kite Pharma, Inc. 555 Kroger Specialty Pharmacy 142 Kyowa Kirin, Inc 231 L&B Splash Blocker 245 Lacuna Loft 212 Lediant Biosciences 1006 Leventon, SAU 453 Lexicon Pharmaceuticals Inc Lexicon Pharmaceuticals Inc Lilly Oncology 237 Living Beyond Breast Cancer 128 LOUNGE 449 LOUNGE 649 MD Anderson Cancer Center 465 Medcor, Inc 270 Medix 867 MedQuest USA 240 MedStar Health Nursing 572 Medtronic 560 Memorial Sloan Kettering Cancer Center 476 Merck & Co 711 Merit Medical Systems, Inc. 274 Merrimack 235 Midatech Pharma US 963 Miller Pharmacal Group, Inc. 1115
4 Mount Sinai Health System 865 MPM Medical, Inc. 338 MSD Oncology 327 Multiple Myeloma Research Foundation 218 MyLifeLine Cancer Connection 119 Myriad Genetic 340 National Cancer Institute 1124 National Lymphedema Network, Inc 126 National Marrow Donor Program/Be The Match 228 NCCN Foundation 118 Non-CNE Theater #1 100 Non-CNE Theater # Non-CNE Theater #3 185 Non-CNE Theater # Northside Hospital 464 Novant Health 666 Novartis Oncology 1125 Novartis Oncology 601 Novocure 359 Nurses Service Organization (NSO) 1025 NYU Langone Medical Center 568 Onco OncoLink 129 Oncology.TV 1060 ONS Booth 635 ONS Career Resources 769 ONS Store 435 Outcome Health 1068 Pacific Search Partners Inc 567 Pancreatic Cancer Action Network 214 Paxxo 1035 Pfizer Oncology 136 Pfizer Oncology 307 Pfizer Oncology 425 PFM Medical Inc. 459 Pharmacyclics 919 Physicians' Education Resource, LLC 839 Prometheus Laboratories Inc. 362 Puma Biotechnology, Inc. 306 Queasy Pops and Queasy Drops 360 Quest Medical, Inc Quintiles 667 Redex - Udderly Smooth 931 Rowpar Pharmaceuticals 1029 R-Pharm US 1120 RyMed Technologies, LLC 163 Saint Agnes Medical Center 773
5 Salix Pharmaceuticals 243 Sandoz 1113 Sanofi Genzyme 959 Sarcoma Foundation of America 115 Savor Health 970 Seattle Cancer Care Alliance 224 Seattle Genetics 969 Sharsheret 116 Shire 458 Sirtex Medical Inc 938 Society for Immunotherapy of Cancer 222 Soothing Scents 1117 Spectrum Pharmaceuticals, Inc. 227 Stand Up To Cancer 173 Stanford HealthCare 565 Taiho Oncology, Inc. 843 Takeda Oncology 401 Teleflex 935 TESARO 1138 TESARO 411 Teva Oncology 817 The Gideons International 114 The Leukemia & Lymphoma Society 230 The Natural Dentist, Revive Personal Products Comp 1041 The Ohio State University James Cancer 665 The Oncologist 977 Theater 676 Thor Photomedicine 167 TransLite, LLC 229 Triage Cancer 226 UC Davis Health 467 UCLA Health System 566 UCSF Health 768 Unitech Medical, Inc. 761 University Hospitals Cleveland Medical Center 968 University of Virginia Health System 664 University of Washington Medical Center 771 UPMC Talent Acquisition 668 US Bioservices 835 Vanderbilt University Medical Center Recruiting 475 VATA Inc 350 Vidant Health 669 Walgreens 653 Washington, DC 972 WellPartner 261 Zyno Medical LLC 275
Association of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2017 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
Association of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2018 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
Association of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2016 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on Targeted Treatment of Metastatic Non-Small Cell Lung Cancer
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on Targeted Treatment of Metastatic Non-Small Cell Lung Cancer CME Information TARGET AUDIENCE This activity is intended for hematologists,
CME Information. ResearchToPractice.com/AUABladder17 1
What Urologists Want to Know: Addressing Current Questions and Controversies Regarding the Role of Immune Checkpoint Inhibitors in the Management of Bladder Cancer CME Information TARGET AUDIENCE This
NEW AGENTS AND STRATEGIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
NEW AGENTS AND STRATEGIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA CME Information TARGET AUDIENCE This activity is intended for medical oncologists, hematologists and other healthcare providers
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
CME Information. ResearchToPractice.com/ThoracicCancers17/Nontargeted 1
CONSENSUS OR CONTROVERSY: Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients without Targetable Tumor Mutations CME Information TARGET AUDIENCE
Oncology Grand Rounds Series:
Oncology Grand Rounds Series: Part 6 Lymphomas and Chronic Lymphocytic Leukemia CNE Information TARGET AUDIENCE This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners
Save Up To $125 with Early Bird Rates through August 21!
Save Up To $125 with Early Bird Rates through August 21! Experience BIG IDEAS, KEY STRATEGIES, and PRACTICAL TAKEAWAYS that will help transform how you deliver patient care! REGISTER TODAY! accc-cancer.org/oncologyconference
Oncology Grand Rounds
Oncology Grand Rounds Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice Part 4: Non-Small Cell Lung Cancer CNE Information TARGET AUDIENCE This activity
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer A Clinical Investigator Think Tank CME Information TARGET AUDIENCE This activity is intended for medical oncologists,
Meet The Professors: Acute Myeloid Leukemia Edition, 2017
Meet The Professors: Acute Myeloid Leukemia Edition, 2017 CME Information TARGET AUDIENCE This activity is intended for medical oncologists and other healthcare providers involved in the treatment of acute
THE NEW BIOLOGY OF NON-SMALL CELL LUNG CANCER
THE NEW BIOLOGY OF NON-SMALL CELL LUNG CANCER CME Information TARGET AUDIENCE This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
Beyond the Guidelines Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Early and Advanced Breast Cancer
Beyond the Guidelines Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Early and Advanced Breast Cancer CME Information TARGET AUDIENCE This program is intended
Current Strategies and Ongoing Research in the Management of Advanced Prostate Cancer
Current Strategies and Ongoing Research in the Management of Advanced Prostate Cancer CME Information TARGET AUDIENCE This activity has been designed to meet the educational needs of medical and radiation
CME Information. without targetable tumor mutations. ResearchToPractice.com/IASLCNSCLC15 1
Beyond the Guidelines Clinical Investigators Provide Their Perspectives on Current Treatment Strategies and Ongoing Research in the Management of Non-Small Cell Lung Cancer without Targetable Tumor Mutations
POST-ASH Issue 4, Results from the Phase III RESPONSE Trial of Ruxolitinib versus Best Available Therapy for Patients with Polycythemia Vera
POST-ASH Issue 4, 2015 Results from the Phase III RESPONSE Trial of Ruxolitinib versus Best Available Therapy for Patients with Polycythemia Vera For more visit ResearchToPractice.com/5MJCASH2015 CME INFORMATION
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
2014 Annual Report. Disseminate the latest and best information impacting the practice of hematology/oncology to members.
Association of Northern California Oncologists 2014 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
POST-ASH Issue 2, Phase I/II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Relapsed/ Refractory CLL
POST-ASH Issue 2, 2016 Phase I/II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Relapsed/ Refractory CLL For more visit ResearchToPractice.com/5MJCASH2016 CME Information OVERVIEW OF ACTIVITY
KEYNOTE PRESENTATION. Edward A Stadtmauer, MD and Patricia Mangan, MSN, CRNP
AGENDA Access Pre/Post Tests and Presentations: PennMedicine.org/Abramson/BloodCME Password: Blood2018 (case sensitive) For Free Wi-Fi use HHonors Promotion Code: phlph2218 7:30 am Registration and Continental
Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
Clinical Practice Guidelines & Quality Cancer Care. Conference Dates. March 14 18, Exhibit Dates. March 15 & 16, 2012
Dates NEW Advocacy/Non-Profit Section in registration foyer Reserve Your Premier Exhibit Space Today! Features The NCCN features an expanded focus on quality issues related to cancer care, challenges in
Oncology Grand Rounds Series:
Oncology Grand Rounds Series: Part 1 Cancer Immunotherapy CNE Information TARGET AUDIENCE This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical
An Audio Review Journal for Nurses Bridging the Gap between Research and Patient Care
ONU VOL 4 ISSUE 1 LUNG CANCER EDITION An Audio Review Journal for Nurses Bridging the Gap between Research and Patient Care FACULTY INTERVIEWS David R Spigel, MD Mollie Reed, MSN, RN, ACNP-BC Lecia V Sequist,
Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
2016 Sponsor and Exhibitor Prospectus
2016 Sponsor and Exhibitor Prospectus September 30 October 1, 2016 New York Marriott Marquis 1535 Broadway New York, New York Returning to New York City in 2016! Join the National Comprehensive Cancer
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer
ISSUE 1 2015 New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer Proceedings from a Clinical Investigator Think Tank F A C U L T Y David P Carbone, MD, PhD Mark G Kris,
8TH SUMMIT & EDUCATIONAL PROGRAM
2 018 E X H I B I TO R P R O S P E C T U S 8TH SUMMIT & EDUCATIONAL PROGRAM OCTOBER 29-31, 2018 NEW YORK ATHLETIC CLUB, NEW YORK, NY www.avbcconline.org Eighth Summit & Educational Program 1 8TH SUMMIT
S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
POST-SABCS Issue 1, 2013 S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
ANCO FAX News. Vol. 18, No. 3 February 8 th, The ANCO FAX News has information for every member of your practice or organization. Pass it along!
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
VISITING PROFESSORS. CME Information
VISITING PROFESSORS Clinical Investigators Provide Their Perspectives on Current Cases and Emerging Research in the Management of Hodgkin and Non-Hodgkin Lymphomas and Multiple Myeloma CME Information
POST-SABCS Issue 4, CALOR Trial of Adjuvant Chemotherapy for Local or Regional Recurrence of Breast Cancer
POST-SABCS Issue 4, 2013 CALOR Trial of Adjuvant Chemotherapy for Local or Regional Recurrence of Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013 CME Information OVERVIEW OF ACTIVITY
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
Head & Neck/Thyroid. Recall the efficacy of promising investigational checkpoint inhibitors and EGFR inhibitors being evaluated in SCCHN.
Head & Neck/Thyroid C M E I n f o r m a t i o n TARGET AUDIENCE This activity is intended for medical oncologists, hematologyoncology fellows and other healthcare providers involved in the treatment of
Clinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
SPECIAL EDITION Issue 2, 2011
SPECIAL EDITION Issue 2, 2011 Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM For more visit
Preliminary Program. SAKK Semi-Annual Meeting November 22 & 23. Zurich Marriott Hotel Neumühlequai 42, 8006 Zurich
Preliminary Program SAKK Semi-Annual Meeting 2018 November 22 & 23 Zurich Marriott Hotel Neumühlequai 42, 8006 Zurich WELCOME NOTE Dear friends of SAKK, dear Madam or Sir, dear colleagues It is our pleasure
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
PARP Inhibition in the Management of Ovarian and Other Gynecologic Cancers
Addressing Current Questions and Controversies: PARP Inhibition in the Management of Ovarian and Other Gynecologic Cancers (Part 1 of a 2-Part Series) CME Information TARGET AUDIENCE This activity is intended
New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
SickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
Adil Daud, MD Mario Sznol, MD Omid Hamid, MD Kim Margolin, MD. 2 Audio CDs
DOU 2014 V OL 4 ISSUE 1 Systemic Management of Malignant Melanoma and Basal Cell Carcinoma Bridging the Gap between Research and Patient Care F A C U L T Y I N T E R V I E W S Adil Daud, MD Mario Sznol,
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
Targeted Treatment of Non-Small Cell Lung Cancer
Targeted Treatment of Non-Small Cell Lung Cancer Current Algorithms and New Agents CME Information TARGET AUDIENCE This activity is intended for hematologists, medical oncologists and other healthcare
ANCO FAX News. Vol. 17, No. 13 July 27 th, The ANCO FAX News has information for every member of your practice or organization. Pass it along!
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
(SaVe_ThE_DaTe) ONS Triad Times. Newsletter of the Piedmont Triad Chapter of the Oncology Nursing Society (PTONS) Upcoming PTONS Chapter Events
ONS Triad Times Newsletter of the Piedmont Triad Chapter of the Oncology Nursing Society (PTONS) Presidents' Message The winter months bring about a time of thankfulness as well as reflection. Looking
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
To register or to learn more please visit:
A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers When Saturday, October 29, 2016 8:00 AM to 4:00 PM Where JW Marriott
SPECIAL EDITION Issue 2, 2011
SPECIAL EDITION Issue 2, 2011 First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment- Emergent BCR-ABL Mutations in Patients Who Received Nilotinib
Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum- Sensitive Recurrent Ovarian Cancer
SPECIAL EDITION Issue 1, 2011 Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum- Sensitive Recurrent Ovarian Cancer For more visit ResearchToPractice.com/5MJCASCO2011
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
Critical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
Exhibit and Support Prospectus
2018 Exhibit and Support Prospectus #BMTTandem18 Comprehensive Update on Blood and Marrow Transplantation and Cellular Therapies Laboratory Research Clinical Investigations Patient Care OVERVIEW 2018 BMT
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
JAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
A Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
ANCO FAX News. Vol. 18, No. 2 January 25 th, The ANCO FAX News has information for every member of your practice or organization. Pass it along!
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
Program. SAKK Semi-Annual Meeting November 23 & 24. Zurich Marriott Hotel Neumühlequai 42, 8006 Zurich
Program SAKK Semi-Annual Meeting 2017 November 23 & 24 Zurich Marriott Hotel Neumühlequai 42, 8006 Zurich WELCOME NOTE Dear friends of SAKK, dear Madam or Sir, dear colleagues It is our pleasure to invite
Industry Supported Symposium Steering improved outcomes in non-driver mutation lung cancer: progress and challenges
IASLC 19 th World Conference on Lung Cancer Industry Supported Symposium Steering improved outcomes in non-driver mutation lung cancer: progress and challenges Chaired by Mark A. Socinski With Keith Kerr,
An Audio Review Journal for Surgeons Bridging the Gap between Research and Patient Care
BCU SURGEONS 2017 VOL 15 ISSUE 1 An Audio Review Journal for Surgeons Bridging the Gap between Research and Patient Care FACULTY INTERVIEWS William J Gradishar, MD Tari King, MD Joseph A Sparano, MD Seema
Quality Medical Donations
PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged
Dissecting the Decision
Dissecting the Decision Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Non-Small Cell Lung Cancer CME Information TARGET AUDIENCE This activity is intended for
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
Poster Presented at the 2014 American College of Rheumatology Annual Meeting
Poster Presented at the 2014 American College of Rheumatology Annual Meeting Anne Winkler 1 James Mossell 2 Edmund MacLaughlin 3 Drew Johnson 4 J. Timothy Harrington 5 1 Winkler Medical Practice LLC, Springfield,
Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
ANCO FAX News. Vol. 17, No. 14 August 10 th, The ANCO FAX News has information for every member of your practice or organization. Pass it along!
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
Association of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2010 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
Insights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
Jashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
Editorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
SPECIAL EDITION Issue 1, 2011
SPECIAL EDITION Issue 1, 2011 Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib For more visit
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
AUGS PFD Week 2018 Exhibitor Priority Points List
AUGS PFD Week 2018 Exhibitor Priority Points List Company Previous Priority Points 2017 Attendance Sq. Ft. Corporate Members 2018 Total Points Boston Scientific 48 1 6 1 56 Medtronic, Inc 50 1 4 1 56 Coloplast
Real-Life Decisions. Proceedings from a Case-Based Symposium on the Management of Early and Advanced Breast Cancer
Real-Life Decisions Proceedings from a Case-Based Symposium on the Management of Early and Advanced Breast Cancer Featuring Faculty Perspectives on New Data Sets Presented at the 33 rd Annual San Antonio
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer Proceedings from a CME Satellite Symposium at the 30 th Annual San Antonio Breast Cancer Symposium
Dissecting the Decision
Dissecting the Decision Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Gastrointestinal Cancers CME Information TARGET AUDIENCE This activity is intended for
ANCO FAX News. Vol. 18, No. 1 January 11 th, The ANCO FAX News has information for every member of your practice or organization. Pass it along!
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
Targeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
ANCO FAX News. Vol. 17, No. 19 November 2 nd, 2018
ANCO FAX News Association of Northern California Oncologists Post Office Box 151109, San Rafael, California 94915-1109 Voice: (415) 472-3960 FAX: (415) 472-3961 execdir@anco-online.org www.anco-online.org
Sunday, May 7, :00 PM 6:30 PM Buffet; 6:30 PM 8:00 PM Presentation Sheraton Grand, Chicago Ballroom 8-10
Sunday, May 7, 2017 6:00 PM 6:30 PM Buffet; 6:30 PM 8:00 PM Presentation Sheraton Grand, Chicago Ballroom 8-10 www.cmeoutftters.com/uccase17 Provided by This program is not affiliated with Digestive Disease
Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
Patient Reported Outcomes in an Era of Immunotherapy Drug Development. David Cella, PhD Northwestern University Chicago, IL, USA
Patient Reported Outcomes in an Era of Immunotherapy Drug Development David Cella, PhD Northwestern University Chicago, IL, USA Disclosures Research Grants: National Institutes of Health, Patient Centered